These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 27072201)

  • 1. Human worth in the era of market forces.
    Huilgol N
    J Cancer Res Ther; 2016; 12(1):1. PubMed ID: 27072201
    [No Abstract]   [Full Text] [Related]  

  • 2. PET scanning: worth the cost in cancer? Not only worth the cost, but sometimes a cost-cutter!
    Rohren EM
    Oncology (Williston Park); 2014 May; 28(5):390, 392. PubMed ID: 25004651
    [No Abstract]   [Full Text] [Related]  

  • 3. Putting a price on hope.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(17):1274-5. PubMed ID: 22914787
    [No Abstract]   [Full Text] [Related]  

  • 4. Financial toxicity in cancer care-Edging toward solutions.
    Goldstein DA
    Cancer; 2017 Apr; 123(8):1301-1302. PubMed ID: 28218808
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global disparities in cancer care: the ABCD for access and the inverse care law.
    Sarin R
    J Cancer Res Ther; 2011; 7(3):249-50. PubMed ID: 22044802
    [No Abstract]   [Full Text] [Related]  

  • 7. The cost of cancer.
    Cromwell J; Gertman P
    Laryngoscope; 1979 Mar; 89(3):393-409. PubMed ID: 107379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment in cancer: a personal view from public health.
    Waugh N
    Eur J Cancer; 2006 Nov; 42(17):2876-80. PubMed ID: 17008094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: Human worth in the era of market forces.
    J Cancer Res Ther; 2016; 12(2):1106. PubMed ID: 27461710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 11. Taking quality of life into account in health economic analyses.
    Weeks J
    J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and care planning. Forward planning.
    Torjesen I
    Health Serv J; 2011 Apr; 121(6252):suppl 2-3. PubMed ID: 21717619
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer therapy--economic aspects].
    Catane R; Catane H; Rozencweig M
    Harefuah; 1995 Feb; 128(3):182-5. PubMed ID: 7759013
    [No Abstract]   [Full Text] [Related]  

  • 15. [The cost of cancer, why? why?].
    Cappelaere P
    Bull Cancer; 2003 Nov; 90(11):937. PubMed ID: 14706895
    [No Abstract]   [Full Text] [Related]  

  • 16. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 17. What price affordable access?
    Nat Biotechnol; 2013 Jun; 31(6):467. PubMed ID: 23752409
    [No Abstract]   [Full Text] [Related]  

  • 18. What are cancer patients willing to pay for prophylactic epoetin alfa?--A cost-benefit analysis.
    Orhan B; Yalçin S
    Cancer; 1999 Sep; 86(6):1095-6. PubMed ID: 10491539
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cytostatic therapy in cancer--a SBU report].
    Glimelius B; Nygren P; Lamnevik G
    Lakartidningen; 2001 Apr; 98(16):1905-10. PubMed ID: 11370407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost analysis of hospice versus non-hospice care: positioning characteristics for marketing a hospice.
    Oji-McNair K
    Health Mark Q; 1985; 2(4):119-29. PubMed ID: 10311206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.